Cellular Immunotherapy—Highlights from TCT 2021

ThinPrep cytologic test combined with HPV typing to evaluate the degree of cervical diseases and the relationship between HPV typing and the pathological results of patients with atypical squamous cells of undetermined significance: a diagnostic test

“…However, false positive or false negative results will occur if HPV typing is used alone, and it is impossible to know whether there is persistent infection, or whether there is cervical disease and its stage (17). One study found that the TCT or HPV typing alone have limitations in the diagnosis of cervical diseases, which may be affected by various factors, such as more keratinocytes, less living cells, bleeding, and vaginitis, in the sampled samples, and joint screening can effectively improve the detection level (18). Ma et al (19) evaluated the application value of TCT and HPV typing in women's cervical cancer screening and found that the combined use of the 2 tests improves the positive detection rate and sensitivity and reduces the missed diagnosis rate.…”

“…For the TCT positive patients, an HPV nucleic acid typing test kit produced by Guangdong Kaipu Biotechnology Co., Ltd. (Guangdong, China) was used after sample labeling. HPV high-risk types include subtypes 16,18,31,33,35,39,45,51,52,53,56,58,59, 66, 68, 73, 82, and 83, and HPV low-risk types include subtypes 6, 11, 42, 43, and 81. Detection principle: deoxyribonucleic acid (DNA) chip technology combining polymerase chain reaction in-vitro amplification and DNA reverse dot blot hybridization were used to design primers according to the genetic characteristics of HPV, and amplify the target fragments of the above different types of HPV genotypes.…”